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ABSTRACT
Objective: SPECT/CT has numerous advantages over planar and traditional 
SPECT images. The aim of this study was to evaluate the role of post-radioiodine 
therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk 
classification and in prediction of late prognosis. 
Patients and methods: 323 consecutive patients were investigated after their 
first radioiodine treatment (1100–3700 MBq). Both whole body scan and SPECT/
CT images of the head, neck, chest and abdomen regions were taken 4–6 days after 
radioiodine therapy. Patients were re-evaluated 9–12 months later as well as at the 
end of follow up (median 37 months).  
Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of 
patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 
patients, respectively, resulting in early reclassification of 115 cases (36%). No 
evidence of disease was found in 251 cases at 9–12 months after radioiodine treatment 
and 269 patients at the end of follow-up. To predict residual disease at the end of 
follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk 
classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%, 
62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference 
between cohorts of the two institutions when data were analyzed separately. 
Conclusions: Based on our bi-institutional experience, the accuracy of post-
radioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk 
classification systems in the prediction of long-term outcome of DTC.
INTRODUCTION
The worldwide incidence of thyroid cancer has 
continuously increased during the last few decades. This 
rise can be attributed to the increased diagnosis of occult 
cancers through the use of neck ultrasound and other 
techniques of diagnostic neck imaging [1–5]. In Hungary, 
approximately 800 new cases were registered by the 
National Cancer Registry and Biostatistics Center in 2014 
(http://www.onkol.hu/hu/nemzeti_rakregiszter, accessed 
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in February 07, 2017). Although the use of improved 
techniques leads to earlier and more accurate diagnosis, 
it may result in overdiagnosis and overtreatment; there is 
an urgent need to better distinguish the high-risk patients 
requiring therapy from those who do not need radioiodine 
after surgery, or may not need treatment at al. [3].
Patients with differentiated thyroid cancer (DTC) 
usually have a favorable prognosis with high cure rates; 
however, lifelong follow-up is required as potentially 
curable local recurrences and distant metastases may occur 
even decades later [6–8]. The conventional and effective 
treatment consists of surgical management followed 
by radioiodine (RAI) ablation of thyroid remnants and 
thyroid-stimulating hormone (TSH) suppressive therapy 
[6, 7]. Recently, the universal use of remnant ablation after 
surgery has been debated and mainly restricted to advanced 
disease [8]. However, radioiodine therapy has additional 
benefits, e.g. the destruction of undetected residual tumor 
foci and the ablation of normal thyroid tissue which 
facilitates the detection of recurrent disease during follow 
up. The information obtained through the posttherapeutic 
131I whole-body scan (WBS) or single photon emission 
computed tomography/computed tomography (SPECT/
CT) may reveal previously undiagnosed tumor foci 
[9–12]. Planar WBS is routinely performed after 
radioiodine treatment; however, SPECT/CT is proven 
to be more accurate in the evaluation of residual disease 
[13–16]. Hybrid systems − integrating a SPECT camera 
with a computed tomography (CT) scanner in one gantry 
− have been in use since 2001, and in the last 5 years the 
application of SPECT/CT imaging system is gaining more 
importance [17]. In comparison to WBS, SPECT/CT adds 
simultaneous 3D anatomic mapping to functional imaging 
[18]. The recognition of artifacts is easier and metastatic 
foci without radioiodine uptake are also detected [19]. 
SPECT/CT significantly ameliorates the diagnosis and 
staging, and differentiates between benign and malignant 
foci of radioiodine accumulation [20].
Postoperative and follow-up management of 
patients with DTC highly depends on risk classification. 
Different risk stratification systems are used by the 
American Thyroid Association (ATA, 2009, 2015) and 
the European Thyroid Association (ETA, 2006). Risk 
stratification systems incorporate data from cancer 
related factors, clinical features, results of first WBS after 
radioiodine therapy and serum thyroglobulin (Tg) level. 
The evaluation of response to initial therapy during the 
follow-up is especially important; risk categories may 
change during the course of disease. The reclassification 
of patients based on post-radioiodine therapy imaging 
influences the management of the disease and the intensity 
of follow-up [21].
The aim of this study was to evaluate the clinical 
utility of combined imaging with SPECT/CT after 
radioiodine treatment of patients with DTC in early risk 
classification and in prediction of late prognosis. These 
results have been compared to the currently used ATA and 
ETA risk stratification systems.
MATERIALS AND METHODS
Characteristics of the patients
After their first radioiodine treatment, 323 
consecutive DTC patients (181 at the University of Pecs 
and 142 at the University of Debrecen) were investigated. 
Demographic data are summarized in Table 1. The female 
to male ratio was 246 to 77. The median age at diagnosis 
was 46 (range 13 to 86) years. All patients were diagnosed 
with DTC; papillary and follicular histotypes were 
identified in 249 and 74 cases, respectively. Among the 
papillary tumors, classical papillary variant was the most 
common subtype (75.1%), while the incidence rate of 
follicular (20.9%), sclerosing (2.4%) and tall cell variants 
(1.6%) was lower. Of the follicular tumors, classical 
variant was the most common (81.1%); Hürthle-cell, 
trabecular and insular variants were diagnosed in 16.2% 
1.3% and 1.3% of cases, respectively. Histology detected 
lymph node involvement in 95 cases, distant metastases 
were known in 12 patients. Thyroglobulin antibody 
(TgAb) positivity was found in 88 patients. 
The study protocol was approved by the Institutional 
Ethics Committees of the University of Pecs and the 
University of Debrecen.
RAI ablation
Based on the surgical and pathological status of the 
tumor, patients were classified into risk groups according 
to the European consensus guideline [7]. Patients with low 
risk for recurrence, younger than 45 years and without 
aggressive histology were treated with 1100 MBq, while 
other patients received 3700 MBq doses. In order to reach 
effective thyroid ablation, two methods of preparation were 
available: thyroid hormone withdrawal or administration of 
recombinant human thyrotropin (rhTSH, 34 patients). Total 
body retention and external radiation dose were measured 
before discharge of the patient. 
Post-radioiodine therapy imaging with WBS and 
SPECT/CT 
Both planar whole body scan (WBS) and SPECT/
CT from the neck and chest were carried out in all patients 
4–6 days after oral administration of 1100–3700 MBq 
radioiodine. Additional SPECT/CT scans of the abdomen 
and pelvis were acquired if suspicious isotope accumulations 
were detected on the WBS. The WBS examination consisted 
of anterior and posterior whole-body images acquired at 
6 cm/min using a DHV SPECT/CT equipment (Mediso, 
Budapest, Hungary). The SPECT/CT unit consisted of dual 
head SPECT, 50 sec/frame, 64 frames, and a low dose, 
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16 slices spiral CT, 120 KeV, 50 mAs [22]. The examination 
was carried out with HEGP collimator. Evaluation of WBS 
and SPECT/CT images were performed by two independent 
nuclear medicine specialists and a radiologist; in case of 
dissent opinion, consensus was achieved. The CERTOP 
01-13044/6/11-07755 Quality Management System was 
applied, which satisfied the requirements of the Hungarian 
Health Care Standards Guide (MEES) 1.0. Identical 
protocols were used at both university centers. 
Risk classification systems and SPECT/CT based 
upgrading and downgrading rules
The risks of recurrence were calculated separately 
according to both the ATA 2009 and ETA 2006 guidelines.
According to the ATA risk stratification system, 
patients can be categorized as (1) low risk, if there are 
no local or distant metastases, all macroscopic tumor has 
been removed, no tumor invasion of local regional tissues, 
no aggressive histology or vascular invasion, no RAI 
uptake outside the thyroid bed on the first posttreatment 
WBS are present; (2) intermediate risk, if there are 
microscopic invasion of the tumor into the perithyroidal 
tissue, or cervical lymph node metastases are present, or 
there is RAI uptake outside the thyroid bed on the first 
posttreatment WBS, or aggressive histology or vascular 
invasion, and (3) high risk, if there is macroscopic tumor 
invasion, or incomplete tumor resection, or distant 
metastases, or thyroglobulinemia out of proportion to what 
is seen on the posttreatment scan [6].
According to the ETA risk classification the risk is 
(1) very low if the tumor is unifocal T1 (≤ 1 cm) N0M0 
and there is no extension beyond the thyroid capsule; (2) 
low, if the tumor is T1 (> 1 cm) N0M0, or T2N0M0, or 
Table 1: Patients’ demographics (n = 323)
Characteristics n (%)
Age (years)
  Median (range) 46 (13–86)
Gender
  Female
  Male
246 (76.2)
77 (23.8)
Tumor histology
Papillary (PTC)
  Classical
  Follicular
  Sclerosing
  Tall cell
Follicular (FTC)
  Classical
  Hürthle cell
  Trabecular
  Insular
249 (77.1)
187 (75.1)
52 (20.9)
6 (2.4)
4 (1.6)
74 (22.9)
60 (81.1)
12 (16.2)
1 (1.3)
1 (1.3)
T stage
  T1
  T2
  T3
  T4
N stage
  N0
  N1
M stage
  M0
  M1
pTNM staging
  I
  II
  III
  IV
143 (44.3)
79 (24.5)
78 (24.3)
21 (6.5)
228 (70.6)
95 (29.4)
311 (96.3)
12 (3.7)
219 (67.8)
28 (8.7)
36 (11.1)
40 (12.4)
TgAb
  Negative
  Positive
235 (72.8)
88 (27.2)
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multifocal T1N0M0; (3) high if the tumor is any T3; any 
T4; any T with N1 or M1 [7].
The risk of recurrence was reevaluated based on 
SPECT/CT results. Patients without RAI uptake outside 
the thyroid bed, except those with aggressive histology, 
were downgraded, while those with detected tumor foci 
were upgraded according to the ATA classification.
The SPECT/CT results served as a basis for 
separating patients into two groups: those with or without 
residual tumor.
Serum Tg, TgAb, neck ultrasound and other imaging 
modalities were used during reclassification of patients 
at 9–12 months after the RAI treatment. No evidence of 
tumor was established with negative neck ultrasound, on-
thyroxine Tg < 0.2 ng/ml or stimulated Tg < 2.0 ng/ml, 
negative TgAb or significant decrease in TgAb titer. 
Incomplete biochemical response was determined if Tg 
was measurable or TgAb titer did not decrease without 
morphological abnormality. Structural disease was 
diagnosed with positive imaging findings. 
TSH, Tg and TgAb measurements
Thyroid stimulating hormone (TSH) was measured 
by an electrochemiluminescence assay (Elecsys® TSH 
assay, Roche, measuring range: 0.005–100 µIU/mL). 
For the University of Pecs patients, Tg and 
TgAb were measured by Elecsys® TG II assay (Roche, 
measuring range of 0.04–500 ng/mL) and Elecsys® anti-
TG assay (Roche, measuring range of 10.0–4000 IU/ml), 
respectively.
For the University of Debrecen patients, Tg was 
measured by chemiluminescent immunoassay (LIAISON®-
Tg, DiaSorin S.p.A., Saluggia, Italy; measuring range: 
0.2–1000 ng/ml). Before December 1, 2014 concentrations 
of TgAb were measured by radioimmunoassay (DYNOtest 
anti-Tg, BRAHMS Diagnostica GmbH, Hennigsdorf, 
Germany; measuring range: 20–2000 U/ml); from 
December 1, 2014 the Elecsys® anti-TG assay (Roche, 
measuring range: 10.0–4000 IU/ml) was used.
Data analysis
Statistical analysis was done with Statistical 
Package for the Social Sciences (SPSS, Inc., Chicago, 
IL, USA, version 22.0). Normality of distribution of data 
was tested by Kolmogorov-Smirnov test. Non-normally 
distributed parameters were presented as median and 
ranges. The diagnostic value of risk classification systems 
to predict the recurrence of tumor at one-year and at the 
end of follow-up was calculated according to Galen. It 
was based on true-positive (TP), true-negative (TN), 
false-positive (FP), and false-negative (FN) results: 
sensitivity: TP/TP+FN, specificity: TN/TN+FP, positive 
predictive value (PPV): TP/TP+FP, negative predictive 
value (NPV): TN/(TN+FN) and diagnostic accuracy: 
(TP+TN)/(TP+TN+FP+FN). The agreement between 
risk stratification systems was calculated with Cohen’s 
kappa coefficient. The diagnostic value of different risk 
classification systems were compared by McNemar 
test. For comparison to other systems, ATA intermediate 
and high risk categories were handled together. To 
identify the determinants of disease outcome, binary 
logistic regression analysis using backward method was 
performed. We considered p < 0.05 to be significant for 
all analyses.
RESULTS
SPECT/CT after the first 131I treatment
No evidence of tumor was detected by SPECT/CT 
in 78.3% of cases (Table 2). Local residual tumor was 
observed in 6 patients (1.8%), lymph node metastases 
were detected in 61 cases (18.8%), lung  and bone 
metastases were found in 13 (4.0%) and 5 (1.5%) patients, 
respectively. In the ATA low risk category (n = 138), 91% 
of patients were tumor-free; lymph node, lung and bone 
metastases were detected in 10, 2 and 1 cases, respectively. 
In the ATA intermediate category (n = 159), no evidence 
of tumor was established in 75%. Lymph node, lung, 
bone and other metastases were diagnosed in 35, 3, 1 
and 1 cases. Posttherapeutic SPECT/CT detected residual 
disease in every forth patient. ATA high risk patients 
(n = 26) were tumor-free only in 18%. Typical images 
of a patient with lymph node and pulmonary metastases 
are shown in Figure 1. Non-radioiodine avid lesions with 
suspected malignancy were detected in 8 cases (2.5%); 
these cases were further investigated by positron emission 
tomography/computed tomography (PET/CT), CT with 
contrast material or magnetic resonance imaging (MRI).
Changes in risk classification and clinical stage 
based on SPECT/CT
The ATA risk stratification includes the WBS based 
RAI uptake outside the thyroid bed. In the present series, 
based on SPECT/CT results, patients with detectable 
residual disease were upgraded: the presence of lymph 
node metastases classified the patients to the intermediate 
risk, while incomplete tumor resection or distant 
metastases classified them to high risk of recurrence 
category. Patients without RAI uptake outside the thyroid 
bed previously categorized having intermediate or high 
risk were downgraded to low risk category except those 
with aggressive histology (Table 3A). Twenty patients 
were upgraded, while 95 patients downgraded, thus, the 
risk categories changed in 115 (35.6%) of cases. The 
risk distribution of the patients according to the ATA 
system before and after SPECT/CT differed significantly 
(p < 0.001), the Cohen’s kappa coefficient was 0.386, 
expressing a moderate agreement. The last ATA guideline 
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does not recommend RAI ablation in the low risk 
category and the RAI therapy should be considered in the 
intermediate risk category. Without RAI treatment 103 
(34.7%) patients would have been misclassified in the low 
and intermediate categories.
Changes in clinical staging were not so profound 
(Cohen’s kappa: 0.894), since the stage of young 
patients did not change even if they had lymph node 
metastases (Table 3B). However, 18 patients were 
upgraded, and 14 of them were classified to stage IV 
category, increasing the number of patients in stage IV 
by 25.9% (p < 0.001). 
Follow-up
Follow-up data were available in 315 cases; the 
median follow-up time was 37 months (range: 9–98 
months). One patient died within one year and seven 
patients were lost for follow-up. Patients with confirmed 
residual tumor were treated by repeated surgery, 
Table 2: The distribution of metastases according to SPECT/CT results in the original ATA risk 
categories (n = 323)
ATA - low risk
(138 patients)
ATA - intermediate risk 
(159 patients)
ATA - high risk 
(26 patients) TOTAL
No evidence of tumor 125 122 6 253
Lymph node metastases 10 35 16 61
Lung metastases 2 3 8 13
Bone metastases 1 1 3 5
Other metastases 0 1 0 1
Figure 1: Anterior and posterior whole body scan (A) and SPECT/CT (B) images of a papillary cancer patient with lymph node and 
pulmonary metastases (arrows).
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RAI, irradiation or sorafenib in 23, 57, 9 and 6 cases, 
respectively, depending on the extension of the disease, 
type of tumor tissue and radioiodine resistance. Serum 
Tg, TgAb, neck ultrasound and other imaging modalities 
were used during long-term follow up. No evidence of 
tumor was found at 9–12 months after the RAI treatment 
in 251 (79.7%) cases. Incomplete biochemical response 
was detected in 20 cases (6.3%), residual tumor was 
evident in 44 patients (13.9%). Eighty-five percent of 
patients were tumor-free at the end of follow-up period. 
The incomplete biochemical response decreased to 2.5% 
(8 cases) while 12.1% (38 cases) of patients suffered 
from persistent thyroid cancer, seven of them died due 
to this disease.
Comparison of the diagnostic value of the 
currently used risk stratification systems and 
SPECT/CT
Sensitivity, specificity, positive and negative 
predictive values and diagnostic accuracy of risk 
classification systems and SPECT/CT based on follow-up 
data at 9–12 months after radioiodine therapy are presented 
in Table 4A. All methods had acceptable sensitivity 
and NPV to predict the presence of DTC; however, the 
sensitivity of SPECT/CT compared to the ATA system 
was significantly lower (61% to 77%, p = 0.021). The 
ATA classification had the lowest specificity (47%) and 
diagnostic accuracy (53%) compared to the other systems 
tested (p < 0.001). The modification of ATA classification 
based on SPECT/CT findings significantly improved the 
specificity (73%) and diagnostic accuracy (72%) of this 
method (both p < 0.001). The results of SPECT/CT alone, 
without any other data, had the highest specificity (88%) 
and diagnostic accuracy (83%, p < 0.001).
The usefulness of risk classification systems and 
SPECT/CT to predict the presence of thyroid cancer 
at the end of follow-up is shown on Table 4B. The 
reclassification of patients at one year was included in 
the analysis. No significant differences in sensitivities 
were found except in case of reclassification at one year, 
which was 100%. Specificity of the individual parameters 
differed significantly, the highest value was also found 
in case of one-year reclassification (93%, p < 0.01). 
Reclassification of patients at one year resulted in 
excellent diagnostic accuracy (94%). The specificity and 
the diagnostic accuracy of SPECT/CT alone were also 
high (87% and 84%), being significantly better (p < 0.01) 
than the values of the ATA and ETA risk stratification 
systems (ATA: 47% and 51%, ETA: 61% and 63%, 
respectively). The completion of ATA classification by 
SPECT/CT results provided better specificity (73%) and 
diagnostic accuracy (74%) than the ATA classification 
(p < 0.001). The diagnostic accuracy provided by the 
SPECT/CT to predict the presence or relapse of DTC at 
the end of follow-up was similar to the result of the one-
year reclassification (p = 0.59). However, SPECT/CT 
results are obtained one year earlier. Diagnostic accuracies 
of different risk stratifications according to disease stages 
were also calculated (Table 5).  The diagnostic accuracies 
of SPECT/CT at the end of follow-up in stage I, II, III and 
IV were 84.6%, 89.3%, 94.3% and 71.1%, respectively; 
these values were significantly higher than the diagnostic 
values of ATA and ETA risk stratifications in every stage.
The role of SPECT/CT in predicting the disease 
outcome was further investigated by binary logistic 
regression analysis; age, TNM stage, clinical staging, 
histology, ATA, ETA risk classification and SPECT/CT 
were included to the model. The age, T, M stage and the 
SPECT/CT result proved to be the independent predictors 
Table 3: Changes in ATA risk classification and clinical stages based on SPECT/CT results 
A) ATA risk classification
Before SPECT/CT
low intermediate high TOTAL
Af
te
r 
SP
EC
T/
C
T low 124 83 5 212
intermediate 11 70 7 88
high 3 6 14 23
TOTAL 138 159 26 323
B) Clinical stages
Before SPECT/CT
I II III IV TOTAL
Af
te
r S
PE
C
T/
C
T I 208 0 0 0 208
II 1 26 0 0 27
III 3 0 31 0 34
IV 7 2 5 40 54
TOTAL 219 28 36 40 323
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of the outcome at one year. These determining factors 
were completed by ETA risk at the end of follow-up. 
SPECT/CT results were the strongest predictors in both 
models (p < 0.001).
DISCUSSION
The postoperative management of DTC is based on 
the risk stratification of patients. However, different risk 
classification systems are used in the US, in Europe, and 
in other parts of the world [6, 7]. The risk classification 
mainly rests on the pathological results and surgical 
findings. The ATA risk classification contains the results 
of WBS after RAI; however, performing WBS is not 
obligatory. In the last few years several articles have been 
published evaluating the advantages of additional SPECT/
CT over WBS alone in the management of DTC patients 
[11, 17]. Investigating 148 consecutive patients, SPECT/
CT significantly reduced the number of equivocal findings 
on WBS and simultaneously was more accurate in the 
characterization of focal iodine accumulation in one fifth 
of patients [23]. The important diagnostic impact and the 
superiority of SPECT/CT over planar scintigraphy in cases 
of inconclusive lesions were also highlighted by others 
[24–30]. Despite of the obvious advantages of the hybrid 
imaging method, it is not a routine procedure in the world.
In this study, the role of SPECT/CT was evaluated in 
early risk classification of patients with DTC and in prediction 
of long-term prognosis compared to the risk of relapse 
determined by ATA and ETA risk classifications. To our best 
knowledge, so far our study has had the largest number of 
DTC patients with the longest follow-up time investigated 
by SPECT/CT. Moreover, this is the first study where the 
diagnostic value of combined imaging with additional SPECT/
CT to predict the long-term outcome of DTC was compared to 
the usefulness of ATA and ETA risk stratifications. 
Residual tumor was detected by post-radioiodine 
SPECT/CT in 22% of patients and this was unexpected 
in the majority of cases. The results of SPECT/CT 
basically modified the management in a considerable ratio 
of patients. The information about the lack of residual 
disease was equally important. The ratio of reclassified 
cases by SPECT/CT was high (36%). The majority of 
reclassifications moved the patients towards lower risk 
Table 4: Comparison of the diagnostic value of the currently used risk stratification systems and 
SPECT/CT
A) At one-year after RAI treatment
Sensitivity Specificity PPV NPV Diagnostic accuracy
ATA 76,6 47,4 27,1 88,8 53,3
ETA 70,3 62,2 32,1 89,1 63,8
ATA after SPECT/CT 65,6 73,3 38,5 89,3 71,7
SPECT/CT 60,9* 88,0** 56,5 89,8 82,5***
Positive predictive value (PPV), negative predictive value (NPV), Risk stratification of American Thyroid Association (ATA), 
Risk stratification of European Thyroid Association (ETA), Risk stratification of American Thyroid Association after SPECT/
CT (ATA after SPECT/CT) and SPECT/CT alone (SPECT/CT). 
*Sensitivity of SPECT/CT compared to the ATA classification was significantly lower (p = 0.021).
**Specificity of SPECT/CT was significantly higher than any other classification (p < 0.001).
***Diagnostic accuracy of SPECT/CT was significantly better than any other classification (p < 0.001).
B) At the end of follow-up (median 37 months, n = 315)
Sensitivity Specificity PPV NPV Diagnostic accuracy
ATA 80,4 46,5 20,4 93,3 51,4
ETA 73,9 60,6 24,3 93,1 62,5
ATA after SPECT/CT 78,3 72,9 33,0 95,1 73,7
SPECT/CT 71,7 86,6** 47,8 94,7 84,4***
Risk at 1 year 100* 93,3** 71,9 100 94,3***
*No significant differences in sensitivities were found except in case of one-year reclassification (p < 0.01).
**Specificities of the individual parameters differed significantly, the one-year reclassification had the highest value (p < 0.01). 
The specificity of SPECT/CT was also significantly better than the values of the ATA and ETA risk classifications (p < 0.001).
***Diagnostic accuracy of one-year reclassification was excellent but not significantly better than that of SPECT/CT 
(p = 0.59). Both method provided better prediction than ATA, ETA and ATA after SPECT/CT classifications (p < 0.01).
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categories. This reclassification influences the treatment 
and follow-up e.g. the TSH target values and the frequency 
of follow-up visits. The detection of non-RAI avid lesions 
by SPECT/CT has also crucial importance as the loss of 
RAI accumulating capability means that this tumor will be 
resistant to RAI treatment and other treatment options are 
required e.g. irradiation or sorafenib treatment.
In prognostic models of disease outcome evaluated 
by binary logistic regression analysis, age, T, M stage and 
SPECT/CT results were found as independent predictors; 
The result of SPECT/CT was the strongest determining 
factor both at one-year evaluation and at the end of 
follow-up.
We tested two different applications of the post-
radioiodine therapy SPECT/CT. Using the ATA risk 
categories, a large proportion of patients had to be 
reclassified based on the SPECT/CT results. Further, 
when post-radioiodine therapy SPECT/CT was used 
as the sole predictor of outcome, its specificity and 
diagnostic accuracy was significantly higher than any of 
the other currently used risk stratification systems. Using 
the SPECT/CT results alone, its sensitivity in predicting 
residual disease at one-year was lower than that of the 
ATA classification without SPECT/CT data; however, this 
difference disappeared by the end of follow-up. The lower 
sensitivity may be explained by the fact that very small 
metastatic foci are below the detection limit of SPECT/CT. 
The response to the initial therapy is essential in 
determining long-term outcome. It has also been proven 
in our investigation that reclassification of patients at 
one-year based on the residual disease has the highest 
sensitivity, specificity and diagnostic accuracy predicting 
long-term outcome.
It is worth to mention that the ratio of follicular 
cancer (with potentially poor prognosis) was relatively 
high in our patients’ cohorts, probably due to marginal 
iodine deficiency in Hungary. The ratio of TgAb positive 
patients was also higher than expected [31, 32]. In TgAb 
positive cases, Tg cannot be used as a tumor marker for 
the follow-up. Therefore, the role of imaging methods 
in the TgAb positive patient population is even more 
important. 
In our study, the residual disease was responsible for 
the biochemically or structurally incomplete response in 
the vast majority of patients and not a relapsing tumor was 
detected. It is possible that previous methods e.g. earlier 
Tg assays were not enough sensitive to detect the residual 
disease, however the follow-up time in this study is not 
enough long to withdraw final conclusion.
CONCLUSIONS
In conclusion, SPECT/CT after radioiodine 
treatment is a useful tool in the early classification of 
DTC patients and largely influences treatment strategy. 
ATA and ETA risk classification systems are sensitive and 
have high negative predictive values, but are less specific 
when compared to post-radioiodine therapy SPECT/CT. 
Due to its better diagnostic accuracy, post-radioiodine 
therapy SPECT/CT can greatly facilitate staging, risk 
classification and management of DTC. We suggest that 
post-radioiodine therapy SPECT/CT should be included 
in the risk classification of patients with DTC.
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